Mesenteric Panniculitis (MP): A Frequent Coincidental CT Finding of Debatable Clinical Significance

Panniculitis mesenterialis (PM): ein häufiger CT-Zufallsbefund mit umstrittener klinischer Relevanz

Authors
Özlem Gögebakan¹, Martin A. Osterhoff², Thomas Albrecht¹

Affiliations
1 Department for Radiology and Interventional Therapy, Vivantes Klinikum Neukölln, Berlin, Germany
2 CBF, Department for Endocrinology, Diabetes and Nutrition, Charité – Universitätsmedizin Berlin, Germany

Key words
abdomen, CT, mesentery, inflammation, lymphoma, paraneoplastic phenomenon

received 22.09.2017
accepted 14.05.2018

Bibliography
DOI https://doi.org/10.1055/a-0633-3558
Published online: 6.9.2018
Fortschr Röntgenstr 2018; 190: 1044–1052
© Georg Thieme Verlag KG, Stuttgart · New York
ISSN 1438-9029

Correspondence
Frau Dr. Özlem Gögebakan
Institut für klinische und interventionelle Radiologie, Vivantes Klinikum Neukölln, Rudower Str. 48, 12351 Berlin, Germany
Tel.: ++ 49/30/1 30 14 20 71
Fax: ++ 49/30/1 30 14 32 71
oezlem.gogebakan@vivantes.de

ZUSAMMENFASSUNG

Hintergrund Bei einer Panniculitis mesenterialis (PM) handelt es sich um eine unspezifische, chronische Veränderung des mesenterialen Fettgewebes unklarer Ätiologie. Sie ist vorzugsweise bei Männern und häufig im mittleren bis höheren Erwachsenenalter anzutreffen. PM wird in der Regel als Zufallsbefund im Rahmen einer abdominellen CT-Untersuchung festgestellt.

Methoden Es wurde eine umfassende Literaturrecherche in PubMed durchgeführt, bei der Fallberichte und Kohortenstudien einer systematischen Betrachtung unterzogen wurden. Schlüsselwörter waren (und/oder) „Mesenteric Panniculitis“, „Panniculitis mesenterialis“, „mesenteric lymph nodes“, „CT“, „imaging“, „sclerosing mesenteritis“, „case report“, „therapy“.


Kernaussagen:
▪ Die Panniculitis mesenterialis (PM) ist eine unspezifische, chronische Entzündung des mesenterialen Fettgewebes mit charakteristischen Zeichen im CT.
▪ Die PM stellt häufig einen CT-Zufallsbefund dar.
▪ Die wichtigste Differentialdiagnose ist das maligne Lymphom.
▪ Eine Assoziation mit anderen insbesondere malignen Erkrankungen wird diskutiert, lässt sich jedoch nicht eindeutig nachweisen.
▪ Die PM wird äußerst selten klinisch symptomatisch, wenn dann mit z. B. Fieber, Übelkeit, Erbrechen, Bauchschmerzen.

ABSTRACT

Background Mesenteric panniculitis (MP) is histologically characterized by chronic nonspecific inflammation of the adipose tissue of the intestinal mesentery with unclear etiology. MP occurs predominantly in men, mostly in mid to late adulthood. MP is typically found as an incidental diagnosis on abdominal CT.
Gögebakan Ö et al. Mesenteric Panniculitis (MP): A Frequent Coincidental CT Finding of Debatable Clinical Significance. Fortschr Röntgenstr 2018; 190: 1044–1052

**Methods** A comprehensive review of the literature including case reports and cohort studies was performed. Therefore, a global search in PubMed was carried out. Search terms were (and/or) “mesenteric panniculitis”, “panniculitis mesenterialis”, “mesenteric lymph nodes”, “CT”, “imaging”, “sclerosing mesenteritis”, “case report”, “therapy”.

**Results and Conclusion** MP is a relatively common CT finding. The true prevalence seems to be higher than the reported 0.6 % to 2.4 % due to underreporting. The most important differential diagnosis is malignant lymphoma, which may be difficult to distinguish from MP. The majority of patients with MP are clinically asymptomatic and do not require therapy. In rare symptomatic cases, non-specific symptoms like abdominal pain, fever, nausea or vomiting occur. For therapy, glucocorticoids and tamoxifen have been suggested. Several studies suggested that MP is associated with other diseases and might be a paraneoplastic phenomenon, but four recently published case-control studies suggest that MP is an independent non-specific benign age-related phenomenon. However, two further studies show a possible association of MP with malignant lymphoma. The clinical relevance of MP remains the subject of scientific debate.

**Key Points:**
- Mesenteric panniculitis (MP) is a non-specific, chronic inflammation of the mesenteric adipose tissue with characteristic CT signs
- MP is a relatively common incidental finding on abdominal CT
- Malignant lymphoma is the main differential diagnosis
- An association of MP with other diseases including malignancy has been discussed but cannot be confirmed unequivocally
- MP is rarely symptomatic with fever, nausea, vomiting, abdominal pain, or diarrhea

**Citation Format**

**Definition**
Mesenteric panniculitis (MP) is a nonspecific inflammatory condition of the mesenteric adipose tissue first described during abdominal surgery by Jura as early as 1924 [1]. The process usually involves the mesentery of the small bowel, especially at its root, and only rarely involves the mesocolon [2, 3]. On rare occasions, MP may also affect the peripancreatic region, omentum, retroperitoneum, or pelvis [4]. The term “panniculitis” deriving from lat. panniculus = “lobule” (diminutive of pannus = “lobe”) describes a local sheet or layer of inflammatory adipose tissue without explaining the etiology. It was first used for inflammation of subcutaneous adipose tissue like that occurring several weeks after severe cold exposure (coldness panniculitis also known as panniculitis type Rothmann-Makai or lipogranulomatosis subcutanea).

MP is sometimes also referred to as sclerosing mesenteritis [5], mesenteric lipodystrophy [6] or misty mesentery [7]. While these terms have to some extent been confused in the past, the term sclerosing mesenteritis was proposed as an umbrella term by Emory et al. [5]. Inflammatory disorders of the mesenteric root today are usually divided into two distinct pathological subgroups, which can be differentiated by histological criteria, into MP and refractive sclerosing mesenteritis. In MP, fat necrosis predominates, while in refractive sclerosing mesenteritis, which is now seen as a different disease, fibrosis and retraction are the prevailing features, often leading to small bowel obstruction/ileus in affected patients [8, 9].

**Epidemiology**
Initially, Kuhrmeier identified the phenomenon which later was called MP as a mesenteric lipodystrophy with typical macroscopic and histopathological changes of the mesenteric adipose tissue in 9 of 712 autopsies (1.26 %) [10]. Today, the diagnosis of MP is typically made on abdominal cross-sectional imaging, mainly CT, as an incidental finding. In the CT literature, the reported prevalence of MP is around 0.6 – 2.4 % [6, 11, 12]. While some authors report higher prevalence of 2.4 – 7.8 % [13 – 16], Wilkes et al. [17] found a prevalence as low as 0.16 %. The diverging values in these studies may be due to over- or underreporting by radiologists or to selection bias in certain centers. Since radiologists may not always be familiar with MP and its specific imaging findings, underreporting appears likely, so that the true prevalence of MP on imaging can be expected to be higher than described in the literature. A further problem might be that the search for MP in retrospective studies is often carried out by a free text search not always revealing cases in which MP is described by an unconventional term. Many studies also lack the exact description of the search terms making it difficult to evaluate the integrity of the search.

Most of the studies reported a higher prevalence in men than in women (2:1 – 3:1) [3, 5, 11, 13, 18 – 20]. The disorder usually occurs in mid or late adulthood [6, 21] with a mean age above 50 years [11, 12, 15, 21 – 26].

**Etiopathology and association with other disease**
The cause of MP remains obscure and is subject to debate. MP is characterized histologically by chronic nonspecific inflammation of the adipose tissue of the intestinal mesentery. Biopsy samples of MP patients show infiltration of the mesenteric fat with a large number of lipid-laden macrophages scattered among fat cells or fully replacing them, probably representing a reaction to fat necrosis, and dispersed lymphocytic aggregates and lymphoid...
foll ofles. Moreover, a variable degree of fibrosis is noted. Acute inflammatory exudates and vasculitis are absent [11].

A number of different co-morbidities occurring with MP have been described in the literature, mainly in case reports or small series without control groups. From these, it is very difficult to judge if MP was the trigger of the reported comorbidities or their consequence and whether there was any causal association.

Trauma (including recent surgery), infection, ischemia of the mesentery and idiopathic inflammatory disorders such as retroperitoneal fibrosis, sclerosing cholangitis, Riedel thyroiditis and orbital pseudotumor have been implicated in this context. Autoimmunity (some authors suggest an IgG4-related disease [27–29]) in the context of established collagen vascular disease as well as unknown causes have been proposed as possible mechanisms, albeit rather for the manifestation as sclerosing mesentery than for MP [30, 31]. An association with abdominal surgery and diverticulitis has also been reported [3]. Due to the lack of control groups in all these publications, it remains unclear if any of the aforementioned associations were significant or merely coincidental.

MP and its association with malignant and other diseases

As mentioned above, several studies have reported an association of MP with malignancy, i.e., lymphocytic leukemia [32, 33], lymphoma and myeloma [34, 35], malignant neoplasms [6], adenocarcinoma of the endometrium [36], carcinoma of the stomach and pancreas [35], tuberculous lymphadenitis [37]. Kipfer et al. found malignancies in 30% of MP patients [6], a fact which was later confirmed by Daskalogiannaki et al. with an even higher rate of 69.3% [11]. Canyigit et al. reported neoplasia in 17.6% of patients with MP [13] and Wilkes et al. in 38% of their MP patients [17]. In a recent Australian study by Cross et al. including a total of 259 MP patients, only 30% had neoplasia [23]. Overall, lymphoma was the malignancy most frequently associated with MP. According to a systematic review of 13 CT studies, the average rate of malignancy in MP patients was 38% with a range from 8–89% in individual studies; 25% of these malignancies were lymphoma [25]. A recent study also reported an increased prevalence of MP in patients with lymphoma [26].

Most of the authors of the aforementioned studies speculate that MP may be a paraneoplastic phenomenon. With respect to the aim of investigating the association of malignancies with MP, however, all these studies suffer from the crucial limitation of lacking a control group or a design to investigate the prevalence of malignancy in non-MP patients in the same CT cohort.

More recently, several studies with control groups were published, further elucidating whether any of the associated pathologies were more common in patients with MP than in the control groups. Consequently, these studies were designed to validate possible causal interactions between MP and the mentioned comorbidities, especially paraneoplastic phenomena [12, 14, 15, 24–26]. In the first case-control study by Gögebakan et al. with more than 13,000 patients undergoing abdominal CT, 77 patients with MP and 152 control patients matched for year of CT examination, CT protocol, sex, age and abdominal diameter at umbilical level were analyzed [12]. In this study, no significant association with any of the abovementioned entities could be confirmed. With regard to malignancy, the rate was 50.6% in the MP group and 61.2% in controls, i.e., even slightly, albeit not significantly, lower in the MP group. The majority of patients with a severe or very severe grade of MP showed no evidence of malignancy at all. In a subgroup of 39 patients who underwent follow-up CT, the evolution of malignancy and MP grade were analyzed, with no association found. Furthermore, there was no significant difference in the rate of frequent concomitant diseases such as hypertension, diabetes or previous surgery between the two groups [12].

A second case-control study using a similar design by van Putte-Katier followed two years after the first case-control study. The authors found a significant association between malignancies and MP in a post-hoc matched pair analysis; the rate of malignancy was 48.9% in the MP group versus 46.2% in the control group (p < 0.05) [14]. There was a statistically significant (p < 0.05) higher prevalence of subjects with prostatic carcinoma in the MP group (34.8%) compared to control patients (26.3%). During follow-up the number of malignancies increased more strongly in the MP group (p < 0.05) [14]. However, one statistical flaw in the described analysis was the use of a McNemar test, which is only correct for paired samples in terms of evaluating the same subjects in a before-after manner or siblings, but not for different subjects in a matched pair analysis when the number of cases is too low. Consequently, the significance of the association between prostatic carcinoma and MP remains questionable. Unfortunately, concomitant diseases such as inflammatory bowel disease, abdominal surgery, cardiovascular disease, hypertension and diabetes were cited only for subjects with MP but not for controls, thus preventing conclusions on the association of such diseases with MP [14].

A third case-control study published by Protin-Catteau et al. [15] used a similar design as the first case-control studies. In this study with 96 MP patients and 192 controls, the prevalence of co-morbidities as well as malignancies was compared between both groups. The fraction of patients with malignancies did not differ significantly in patients with MP (60.4%) and control patients (59.4%) except for lymphoma and melanoma. Likewise, during a 5-year follow-up, no higher prevalence of neoplasia was found in the MP group. Furthermore, an association between MP and other comorbidities, such as hypertension, diabetes, diverticulitis, etc., could not be verified by Protin-Catteau and colleagues [15].

A fourth case-control study by Scheer et al. also claimed to demonstrate an association of malignancies with MP [26]. The authors compared patients with and without MP from an overall CT population of 5595 patients. The incidence of malignancies was 74.8% in patients with MP compared to 35.2% in the overall population. The highest prevalence of MP was found in patients with Non-Hodgkin Lymphoma (22.6%). One limitation of this study is that the control group was not matched with MP patients, so that e.g. patients in the MP group were significantly older than in the overall population, which in itself may account for a higher incidence of malignancy [26]. Furthermore, it is often difficult to definitely distinguish lymphoma from enlarged lymph nodes in

Gögebakan Ö et al. Mesenteric Panniculitis (MP):... Fortschr Röntgenstr 2018; 190: 1044–1052
the context of MP. Valid markers for MP would be the “fat ring” sign and a pseudocapsule. The authors do not clearly specify which typical radiological criteria of MP accompany the confirmed cases of lymphoma in their study. For example, there is no information on whether the twelve subjects lacking the pseudocapsule sign are the same that also lacked a fat-ring sign. Since “fat-ring” sign and pseudocapsule might be the most suitable markers to diagnose MP [8, 11, 38] in the presence of non-Hodgkin lymphoma, this would have been interesting information. As a result, it remains unclear whether a fraction of the confirmed lymphoma patients might have been spuriously assigned to the MP group [26].

Moreover, the mentioned differences may be due to a slight bias resulting from different populations visiting the respective hospitals or from different matching modalities.

However, in three case-control studies [12, 14, 15] a prevalence for malignancies in the MP group as well as in the control group of approximately 50% is reported or – vice versa – in one case-control study the prevalence of MP in the lymphoma and the control group are similar [39]. Furthermore, a recent cohort study by Buchwald et al. [24] confirms the follow-up data of Gögebakan et al. [12] and Protin-Catteau et al. [15]. In their cohort of 173 patients with verified MP, Buchwald et al. evaluated in a 13-year follow-up (2003–2015) whether patients with or without malignancies differed in terms of the rate of remission or aggravation of MP, and whether the treatment of malignancies influenced the severity of MP. The authors did not find statistical evidence of an association between the course of MP and that of the concomitant malignant disease in any scenario [24].

A systematic review by Halligan et al. [25] of past studies addressing the question of whether or not MP might be a paraneoplastic phenomenon comes to the qualitative conclusion (heterogeneity of the study designs prevented a meta-analysis) that an association between MP and malignancy cannot be determined.

Recently, a case-control study to analyze a possible association between MP and lymphoma was published by Khasminsky et al. [39]. The authors evaluated 166 subjects with Non-Hodgkin-Lymphoma (NHL) and 332 control subjects matched for gender and age by combined CT/PET examinations. In the NHL group the prevalence of MP was the same as in the control group leading to the conclusion that MP and lymphoma are not associated [39].

In a retrospective study without a control group, Ehrenpreis et al. found 359 patients with MP-like findings out of a total of 147 794 subjects with CT scans [40]. Of these 359 patients with MP-like findings, 81 patients had a known cancer history and 19 a newly diagnosed malignancy. The greatest fraction again was patients with lymphoma (36), 27 with a known history and 9 newly diagnosed. Based on the fact that the initial likelihood of an existing malignancy was only 5% and a new diagnosis of cancer was only found in 1.4% of subjects with MP, the authors concluded that a new diagnosis of malignancy in patients with MP-like findings is a rare event. Additionally, the authors concluded from the fact that MP-like signs usually remain stable in patients with known malignancies that MP might be a paraneoplastic phenomenon [40].

### Table 1

<table>
<thead>
<tr>
<th>sign</th>
<th>description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>a well-defined fatty mass at the root of the small bowel mesentry displacing neighboring structures</td>
</tr>
<tr>
<td>2</td>
<td>sign 1 with a higher attenuation than that of retroperitoneal or subcutaneous fat tissue</td>
</tr>
<tr>
<td>3</td>
<td>lymph nodes within this well-defined fatty mass</td>
</tr>
<tr>
<td>4</td>
<td>a hypodense halo surrounding blood vessels and nodes</td>
</tr>
<tr>
<td>5</td>
<td>a hyperdense pseudocapsule surrounding the mesenteric fat with the lymph nodes within</td>
</tr>
</tbody>
</table>

### Table 2

<table>
<thead>
<tr>
<th>score</th>
<th>occurrence/grade</th>
<th>severity of MP</th>
<th>grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>absent</td>
<td>sum of scores of MP signs</td>
<td>grade</td>
</tr>
<tr>
<td>1</td>
<td>discrete</td>
<td>3–4</td>
<td>minimal</td>
</tr>
<tr>
<td>2</td>
<td>moderate</td>
<td>5–9</td>
<td>moderate</td>
</tr>
<tr>
<td>3</td>
<td>marked</td>
<td>10–15</td>
<td>marked</td>
</tr>
</tbody>
</table>

However, in view of recent case-control studies reporting similar numbers of patients with malignancies but without symptoms of MP, this conclusion appears to be questionable [12, 15, 24, 25].

In conclusion, all of these studies do not provide convincing statistical evidence of an association of concomitant diseases including malignancies with MP [12, 14, 15, 24–26, 39, 40]. All discussed studies are summarized in Table 3.

### Clinical Symptoms

There are no specific clinical symptoms of MP. Nevertheless, patients may present with palpable abdominal mass and symptoms, including abdominal pain, nausea, diarrhea, pyrexia, weight loss and bowel disturbance of variable duration [5, 22, 41–43], especially in rare cases where retraction of the mesentery leads to bowel obstruction or, less commonly, to mesenteric ischemia [6, 28, 44–46]. In most cases of MP, however, clinical symptoms

---

Gögebakan Ö et al. Mesenteric Panniculitis (MP):… Fortschr Röntgenstr 2018; 190: 1044–1052
### Table 3 Summary of studies discussed in the section “MP and its association with malignant and other diseases”

<table>
<thead>
<tr>
<th>Authors</th>
<th>Title</th>
<th>Study design</th>
<th>Follow-up</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gögebakan et al., 2013 [1]</td>
<td>Is mesenteric panniculitis truly a paraneoplastic phenomenon? A matched pair analysis</td>
<td>Retrospective out of 1,348 CT examinations; search for MP; only one malignant group (143), no controls; malignancy: non-malignancy = 107:36</td>
<td>5 years</td>
<td>No significant difference in rates of MP remission between malignancy and non-malignancy groups (20:18%) or between groups where MP was cured or not (21:19%); no difference in rates of MP remission between groups where MP was cured, and no malignancy was apparent (21:19%); MP does not behave like a paraneoplastic phenomenon, more likely as an epiphenomenon of a high number of CT images.</td>
</tr>
<tr>
<td>van Putte-Katier et al., 2014 [14]</td>
<td>mesenteric panniculitis prevalence: review of cross-sectional imaging findings and risk of subsequent malignancy</td>
<td>Retrospective out of 5595 CT examinations; search for MP and malignancies; MP n = 173</td>
<td>13 years</td>
<td>No difference in rates of MP remission between malignancy and non-malignancy group (20:18%) or between groups where MP was cured or not (21:19%); no difference in rates of MP remission between groups where MP was cured, and no malignancy was apparent (21:19%); MP does not behave like a paraneoplastic phenomenon, more likely as an epiphenomenon of a high number of CT images.</td>
</tr>
<tr>
<td>Buchwald et al., 2016 [24]</td>
<td>Mesenteric Panniculitis (MP) – A Predictor of Malignancy</td>
<td>Retrospective out of 44,794 abdominal CT examinations; search for MP-like abnormalities; MP n = 359</td>
<td>5 years</td>
<td>No significant difference of prevalence for MP in people with NHL, compared to people without NHL.</td>
</tr>
<tr>
<td>Protin-Catteau et al., 2016 [15]</td>
<td>mesenteric panniculitis: review of consecutive abdominal MDC examination and its relationship to malignancy</td>
<td>Retrospective out of 3051 MDC examinations; search for MP; case control (94:188), matched for sex and age</td>
<td>5 years</td>
<td>No association of severity of MP with grade or development of malignancies. No association of MP severity with comorbidities.</td>
</tr>
<tr>
<td>Halligan et al., 2016 [25]</td>
<td>mesenteric panniculitis: systematic review of past studies; meta-analysis like; 14 studies included; between 17 and 359 MP patients</td>
<td>Retrospective out of 500,000 CT examinations; search for MP and malignancies; MP n = 173</td>
<td>13 years</td>
<td>No available study can determine an association between MP and subsequent malignancy with certainty.</td>
</tr>
<tr>
<td>Ehrenpreis et al., 2016 [40]</td>
<td>clinical significance of mesenteric panniculitis-like abnormalities on abdominal computed tomography in patients with malignant neoplasms</td>
<td>Retrospective out of 1,179 CT examinations of patients with lymphoma; MP n = 323</td>
<td>5 years</td>
<td>No significant difference of prevalence for MP in people with NHL, compared to people without NHL.</td>
</tr>
<tr>
<td>Scheer et al., 2016 [39]</td>
<td>mesenteric panniculitis (MP) in patients with non-Hodgkin lymphoma (NHL): CT appearances</td>
<td>Retrospective out of 5939 CT examinations; search for MP; only MP (143), no controls; malignancy: non-malignancy = 107:36</td>
<td>5 years</td>
<td>No significant difference of prevalence for MP in people with NHL, compared to people without NHL.</td>
</tr>
<tr>
<td>Khasminsky et al., 2017 [38]</td>
<td>mesenteric panniculitis (MP) in non-Hodgkin lymphoma (NHL): CT features and CT follow-up</td>
<td>Retrospective out of 1,477 CT examinations; search for MP-like abnormalities; MP n = 359</td>
<td>16 years</td>
<td>No significant difference of prevalence for MP in people with NHL, compared to people without NHL.</td>
</tr>
</tbody>
</table>

MP = mesenteric panniculitis; NHL = non-Hodgkin lymphoma; MDC = multidetector row CT; NA = not applicable.
are absent, non-specific and/or atypical [11, 44], arguably indistinguishable from symptoms of concomitant disease.

Abnormal laboratory findings are usually absent or nonspecific. Some previous studies suggested an association with elevated CRP plasma levels or decreased hemoglobin [11, 13], but this was not confirmed by a recent case-control study [12].

Imaging/diagnosis of MP

MP is most commonly diagnosed incidentally by CT carried out for other reasons. According to the accepted definition by Coulier [16], CT diagnosis of MP requires the presence of at least 3 out of 5 typical signs listed in ▶ Table 1 and depicted in ▶ Fig. 1. For diagnosis of MP, it is obligatory that there is no infiltration of neighboring structures. In a few cases calcifications of the mesenteric mass were reported [41]. Four possible grades are assigned to each sign of MP and the grades of all signs are summarized, finally leading to one of the three grades of severity of MP listed in ▶ Table 2. ▶ Fig. 2 shows axial and coronal CTs of mild, moderate and marked MP appearance.

The most important differential diagnosis of MP is malignant lymphoma. Other differential diagnoses are inflammatory pseudotumor, dermoid tumor or pancreatitis.

MP may also be detected by MRI or ultrasound [19, 47]. PET-CT may be an option to distinguish between MP and lymphoma. Zissin et al. and Coulier et al. report on measurement of 18F-FDG uptake as a marker for malignant lymphoma within surrounding MP, with even small lymphoma nodules displaying 18F-FDG uptake [8, 48]. Weiss et al. report on 18F-FDG uptake to distinguish between lymphoma and subcutaneous panniculitis [49]. However, PET-CT may not be sufficient to detect all malignant lymphoma so that biopsy remains advisable to safely rule out malignancy in equivocal cases [50]. CT, however, remains the diagnostic method of choice.
Therapy

Since MP is typically diagnosed as an incidental finding and most patients are asymptomatic, no treatment is warranted in the vast majority of patients [51]. In symptomatic cases, a number of drugs such as progesterone, corticosteroids, azathioprine, and a combination of corticosteroids with colchicine have been tried for treatment of this condition with results reported in small case series [52–54]. Corticosteroids in combination with tamoxifen constitute the preferred first-line therapy. Akram et al. reported on 20 patients treated with prednisolone and tamoxifen with follow-up by assessment of clinical symptoms and abdominal CT studies [18]. Before treatment, CT showed a single soft-tissue mass in the mesenteric root, with calcification in 61% of cases. In 34% of cases subtly increased density of the mesenteric fat with or without discrete soft tissue masses, small retroperitoneal and/or mesenteric lymph nodes, and encasement of mesenteric vessels were found. In the remaining 5% of cases, no abdominal CT was available. After treatment, 12 patients (60%) responded within 12–16 weeks, whereas 6 (30%) showed persistent symptoms and 2 (10%) even progressed. Unfortunately, the authors do not specify the particular changes of MP markers on post-treatment CT [18]. Other medications that have been used with some success include azathioprine, cyclophosphamide, progesterone and thalidomide [51, 53, 54]. Some case reports indicate rare cases where surgery was necessary for symptomatic relief, but in one such publication the CT image of supposed MP did not show the characteristic signs of MP, and pathology and CT findings suggested sclerosing mesenteritis [55]. Thus, case reports should be evaluated carefully with regard to the question of whether all described cases were indeed patients with MP.
**Concluding remarks**

Mesenteric panniculitis (MP) is a nonspecific inflammatory condition of the mesenteric adipose tissue of unknown etiology. It is a relatively common coincidental finding on abdominal imaging with the vast majority of affected patients being asymptomatic. Several studies have suggested an association of MP with neoplastic and other diseases. In particular, there has been much suspicion that MP may be associated with lymphoma, though the reported prevalence strongly varies (7.8–33 %) [6, 11, 12, 14–17, 24, 26, 40, 48, 50, 56]. However, recent studies with control groups showed no convincing statistical evidence of an association of MP with concomitant diseases including malignancies [12, 14, 15, 24–26, 39]. There is evidence from a single study that prostate carcinoma may be more common in patients with MP [14]. The greatest risk to the patient may be that benign MP is confused with a neoplastic disease such as lymphoma. Differentiation between malignant lymphoma and enlarged benign nodules in the context of MP is often difficult and may lead to spurious diagnosis of MP in the presence of lymphoma. There are, however, some reliable typical CT signs of MP such as “fat-ring” signs around nodules and vessels, a pseudocapsule surrounding the mesenteric mass, and the fact that MP has never been shown to infiltrate other organs or neighboring structures, unlike other mesenteric diseases such as lipoma, liposarcoma, lymphoma, and mesenteric carcinoma [8, 11, 38]. Conversely, nodules larger than 10 mm in the short axis diameter are suspicious of being lymphoma-related [11, 13, 19, 47]. Moreover, in contrast to MP, malignant lymphoma often presents with enlarged retroperitoneal or paraaortic lymph nodes.

PET-CT can be helpful in differentiating simple MP from MP co-existing with neoplasia such as lymphoma [57]. The specificity of PET-CT is very high, while the sensitivity is not [8, 40, 57]. Therefore, in a context of neoplasia, biopsy remains advisable in equivocal cases [50].

The scoring system for MP by Coulier et al. [16] is accepted in workgroups carrying out research studies on MP, since the scoring helps to standardize the signs of MP and its grading and makes it possible to compare results across different studies. Nevertheless, this scoring system is mainly relevant for academic purposes and has not become part of the daily clinical routine. The reason might be that the scoring system is not correlated with clinical symptoms and does not allow inference on any clinical relevance for the patient, future complications or a need of therapy.

From the recent studies, no convincing statistical evidence of an association of MP with concomitant diseases including malignancies can be inferred and therapy is usually not necessary in case of mesenteric panniculitis. Therefore, after diagnosis of MP, follow-up imaging is not indicated when lymphoma is reliably ruled out.

**Conflict of Interest**

The authors declare that they have no conflict of interest.

**Literatur**

[1] Jura V. Sulla mesenterite retrattile e sclerosante. Policlinico 1924; 31: 575